Advertisement

Editor Profile

Mark V. Dahl, MD

Associate Editor

About the NEJM Journal Watch Dermatology Board

Mark V. Dahl, MD, is currently Professor of Dermatology, College of Medicine, Mayo Clinic, and Senior Consultant in the Department of Dermatology at Mayo Clinic in Scottsdale/Phoenix, Arizona. He has served as President of the American Academy of Dermatology and as Vice President of the Society for Investigative Dermatology. He is the founder of Camp Discovery, a camping program for children with severe skin diseases. Dr. Dahl is a recipient of the Gold Medal, the American Academy of Dermatology's highest honor, and was named a Master Dermatologist by the organization in 2006. His research has focused on immunology, infections, and inflammatory diseases of the skin, including studies related to immunodeficiency, chemotaxis, granuloma annulare, immunofluorescence, bullous diseases, psoriasis, cutaneous irritation, allergy, rosacea, the epidermal acetylcholine network, and cutaneous fungal infections. Dr. Dahl joined the NEJM Journal Watch Dermatology board in 2007.

Disclosures

Consultant / Advisory board

Ulthera, Inc.; AuBio LifeSciences, LLC; Paris Therapeutics

Equity

Elorac, Inc.; Makucell, Inc.; Paris Therapeutics

Editorial boards

UpToDate

Leadership positions in professional societies

National Rosacea Society (Chairman, Medical Board)

Summaries by Mark Dahl

  • May 19, 2015

    Not Exactly a Silver Bullet

    1. Mark V. Dahl, MD

    Silver sulfadiazine cream impairs wound healing of thermal burns in mouse skin.

  • April 27, 2015

    Holding onto Repigmentation in Vitiligo

    1. Mark V. Dahl, MD

    Twice weekly applications of tacrolimus ointment 0.1% help maintain pigment in vitiligo patients after repigmentation treatments.

  • April 21, 2015

    Rosacea or Photodamage?

    1. Mark V. Dahl, MD

    The redness of erythematotelangiectatic rosacea appears to be caused by inflammation and vasodilation rather than vasodilation alone.

  • March 31, 2015

    Acitretin for Psoriasis

    1. Mark V. Dahl, MD

    Properly used, it is one of the safest systemic agents.

  • March 20, 2015

    Cold Spots

    1. Mark V. Dahl, MD

    New quantitative techniques to measure temperature and time thresholds in patients with acquired cold urticaria affirm the value of standard current treatment.

  • February 27, 2015

    Happy Doctors

    1. Mark V. Dahl, MD

    Dissatisfied physicians are less inclined to give charity care.

Pages